RecruitingPhase 2ketamine

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Sponsored by Stanford University

NCT ID
NCT05940324
Target Enrollment
150 participants
Start Date
2024-02-24
Est. Completion
2028-11

About This Study

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Conditions Studied

Obsessive-Compulsive Disorder

Interventions

  • Ketamine
  • Naltrexone Pill
  • Placebo pill

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:Yes
View full eligibility criteria
Eligibility Criteria for Participants with OCD:

Inclusion Criteria:

* Ages 18-65
* Meet the criteria for OCD diagnosis
* Failed at least 1 prior trial of standard first-line OCD treatment
* Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
* Able to provide informed consent

Exclusion Criteria:

* prior naltrexone or ketamine use/exposure
* Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
* the presence of metal in the body that is contraindicated for MRI scans

Eligibility Criteria for Healthy Volunteers:

Inclusion Criteria:

* Ages 18-65
* Able to provide informed consent

Exclusion Criteria:

* current or past use of psychotropic medication
* pregnant or nursing females
* the presence of metal in the body that is contraindicated for MRI scans

Study Locations (1)

Department of Psychiatry & Behavioral Sciences
Stanford, California, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Pavithra Mukunda, MS
CONTACT
6504972578ocdresearch@stanford.edu
Carolyn I Rodriguez, MD, PhD
CONTACT
(650) 723-6158ocdresearch@stanford.edu
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) | Huxley